Co-Diagnostics is developing molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Co.'s diagnostics systems enable molecular testing for organisms and genetic diseases by automating procedures in both the development and administration of tests. Co.'s technical advance involves an approach to Polymerase Chain Reaction (PCR) test design that eliminates one of the main vexing issues of PCR amplification, the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely interferes with identification of the target DNA. The CODX stock yearly return is shown above.
The yearly return on the CODX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CODX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|